Search clinical trials for: Sunitinib Malate

Total 675 results

Repurposed Therapeutics, Inc.
National Aeronautics and Space Administration (NASA)

Recruiting

Combination of Intranasal Scopolamine and Sensory Augmentation to Mitigate G-transition Induced Motion Sickness and Enhance Sensorimotor Performance

Motion Sickness, Space | Motion Simulation | Parabolic Flight

United States
National Cancer Institute (NCI)

Recruiting

Testing the Addition of Sunitinib Malate to Lutetium Lu 177 Dotatate (Lutathera) in Pancreatic Neuroendocrine Tumors

Metastatic Pancreatic Neuroendocrine Tumor | Pancreatic Neoplasm | Stage III Pancreatic Neuroendocrine Tumor AJCC v8 | Stage IV Pancreatic Neuroendocrine Tumor AJCC v8 | Unresectable Pancreatic Neuroendocrine Tumor

United States, Canada
Exelixis

Recruiting

Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma (STELLAR-304)

Non-Clear Cell Renal Cell Carcinoma

United States, Spain, Korea, Republic of, Italy, Australia, France, Argentina, Brazil, Chile, Czechia, Finland, Germany, Malaysia, Netherlands, Poland, Thailand
Vivent Health
Gilead Sciences

Recruiting

Telehealth as a Modality to Increase the Uptake of PrEP Services in Black and Latino: "e-PrEP" (e-PrEP)

HIV Prevention

United States
University of Colorado, Denver

Recruiting

Losartan + Sunitinib in Treatment of Osteosarcoma

Osteosarcoma

United States
M.D. Anderson Cancer Center
Pfizer

Terminated

Evaluation of Sunitinib Malate in Patients With Von Hippel-Lindau Syndrome (VHL) Who Have VHL Lesions to Follow

Renal Cell Carcinoma | Von Hippel-Lindau Syndrome | Hemangioblastoma

United States
National Cancer Institute (NCI)

Active, not recruiting

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Glioma | Hematopoietic and Lymphoid Cell Neoplasm | Melanoma | Lymphoma | Multiple Myeloma | Recurrent Ovarian Carcinoma | Breast Carcinoma | Recurrent Head and Neck Carcinoma | Recurrent Lung Carcinoma | Recurrent Skin Carcinoma | Gastric Carcinoma | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory... and other conditions

United States, Puerto Rico, Guam
National Cancer Institute (NCI)
Canadian Cancer Trials Group

Active, not recruiting

Testing Cabozantinib, Crizotinib, Savolitinib and Sunitinib in Kidney Cancer Which Has Progressed

Unresectable Renal Cell Carcinoma | Stage III Renal Cell Cancer AJCC v7 | Stage IV Renal Cell Cancer AJCC v7 | Type 1 Papillary Renal Cell Carcinoma | Type 2 Papillary Renal Cell Carcinoma | Metastatic Papillary Renal Cell Carcinoma | Locally Advanced Papillary Renal Cell Carcinoma

United States, Canada
M.D. Anderson Cancer Center
National Cancer Institute (NCI); Exelixis

Active, not recruiting

Cabozantinib or Sunitinib Malate in Treating Participants With Metastatic Variant Histology Renal Cell Carcinoma

Renal Cell Carcinoma | Metastatic Renal Cell Carcinoma | Stage IV Renal Cell Cancer AJCC v8 | Sarcomatoid Renal Cell Carcinoma | Chromophobe Renal Cell Carcinoma | Papillary Renal Cell Carcinoma | Malignant Neoplasms of Urinary Tract | Renal Cell Carcinoma Associated With Xp11.2 Translocations/TFE3... and other conditions

United States
M.D. Anderson Cancer Center
Pfizer

Active, not recruiting

Sunitinib Malate With Hormonal Ablation for Patients Who Will Have Prostatectomy

Prostate Cancer

United States
M.D. Anderson Cancer Center

Active, not recruiting

Intraoperative Acupoint Stimulation to Prevent Post-Operative Nausea and Vomiting (PONV)

Breast Cancer | Post-Operative Nausea and Vomiting

United States
National Cancer Institute (NCI)

Active, not recruiting

Sunitinib Malate in Treating Patients With Thyroid Cancer That Did Not Respond to Iodine I 131 and Cannot Be Removed by Surgery

Recurrent Thyroid Gland Carcinoma | Refractory Thyroid Gland Carcinoma | Stage III Thyroid Gland Follicular Carcinoma AJCC v7 | Stage IV Thyroid Gland Follicular Carcinoma AJCC v7 | Stage IV Thyroid Gland Papillary Carcinoma AJCC v7 | Stage IVA Thyroid Gland Follicular Carcinoma AJCC v7 | Stage... and other conditions

United States
M.D. Anderson Cancer Center
Pfizer

Active, not recruiting

Pre-Surgical Sutent in Renal Cell Carcinoma (RCC)

Renal Cell Carcinoma

United States
National Cancer Institute (NCI)

Active, not recruiting

Sorafenib in Treating Patients With Malignant Gastrointestinal Stromal Tumor That Progressed During or After Previous Treatment With Imatinib Mesylate and Sunitinib Malate

Gastrointestinal Stromal Tumor

United States
Dwight Owen
National Cancer Institute (NCI)

Suspended

Pembrolizumab and Sunitinib Malate in Treating Participants With Refractory Metastatic or Unresectable Thymic Cancer

Thymic Carcinoma

United States
Sidney Kimmel Cancer Center at Thomas Jefferson...
Pfizer

Active, not recruiting

Sunitinib Malate or Valproic Acid in Preventing Metastasis in Patients With High-Risk Uveal Melanoma

Ciliary Body and Choroid Melanoma, Medium/Large Size | Ciliary Body and Choroid Melanoma, Small Size | Iris Melanoma | Stage IIIA Intraocular Melanoma | Stage IIIB Intraocular Melanoma | Stage IIIC Intraocular Melanoma | Stage I Intraocular Melanoma | Stage IIA Intraocular Melanoma | Stage IIB Intraocular... and other conditions

United States
NCIC Clinical Trials Group

Completed

Sunitinib in Treating Patients With Newly Diagnosed Stage II or Stage III Breast Cancer That Can Be Removed by Surgery

Breast Cancer

Canada
National Eye Institute (NEI)

Terminated

Sunitinib Malate to Treat Advanced Eye Disease in Patients With Von Hippel-Lindau Syndrome (VHL3)

Von Hippel-Lindau Syndrome

United States
M.D. Anderson Cancer Center
Bristol-Myers Squibb; Pfizer; Janssen Scientific Affairs, LLC

Completed

Maximal Androgen Depletion Followed by Randomization of Maximal Androgen Ablation With Molecular Targeted Therapies

Prostate Cancer

United States
National Cancer Institute (NCI)

Completed

Sunitinib Malate and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors That Have Not Responded to Chemotherapy

Adult Solid Neoplasm

United States
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Completed

Sunitinib Malate With or Without Gemcitabine Hydrochloride in Treating Patients With Advanced Kidney Cancer That Cannot Be Removed By Surgery

Kidney Cancer

United States
Indiana University
Pfizer

Completed

Exploratory Study of Sunitinib Malate as a Component of Neoadjuvant Therapy for Breast Cancer

Breast Cancer

United States
Pfizer

Completed

Special Investigation For Renal Cell Carcinoma (RCC) Of Sunitinib Malate (Regulatory Post Marketing Commitment Plan)

Carcinoma, Renal Cell
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Completed

A Bioequivalence Study of Sunitinib Malate Capsules.

Renal Cell Carcinoma | Gastrointestinal Stromal Tumors | Pancreatic Neuroendocrine Tumor

China
Pfizer

Completed

Special Investigation For Gist Of Sunitinib Malate (Regulatory Post Marketing Commitment Plan).

Gastrointestinal Stromal Tumors
National Cancer Institute (NCI)

Completed

Cisplatin or Carboplatin, and Etoposide With or Without Sunitinib Malate in Treating Patients With Extensive-Stage Small Cell Lung Cancer

Extensive Stage Lung Small Cell Carcinoma | Recurrent Lung Small Cell Carcinoma

United States
University Health Network, Toronto
Pfizer

Completed

Study Of Sunitinib In Patients With Recurrent Paraganglioma/Pheochromocytoma (SNIPP)

Pheochromocytoma | Paraganglioma

Canada, Netherlands
Ludwig Institute for Cancer Research
Pfizer; Heidelberg Pharma AG

Terminated

Study of Safety and Functional Imaging of cG250 and Sunitinib in Patients With Advanced Renal Cell Carcinoma

Renal Cell Carcinoma (RCC)

Australia
Federation Francophone de Cancerologie Digestive

Withdrawn

Sunitinib Malate and Combination Chemotherapy as Front-Line Therapy in Treating Patients With Metastatic Rectal Cancer That Cannot Be Removed by Surgery

Colorectal Cancer | Metastatic Cancer

France
Roswell Park Cancer Institute
Novartis

Terminated

Panobinostat and Everolimus in Treating Patients With Metastatic or Unresectable Renal Cell Cancer That Does Not Respond to Treatment With Sunitinib Malate or Sorafenib Tosylate

Clear Cell Renal Cell Carcinoma | Stage III Renal Cell Cancer | Stage IV Renal Cell Cancer | Recurrent Renal Cell Cancer

United States
Roswell Park Cancer Institute
Pfizer

Completed

Dalteparin and Sunitinib Malate as First-Line Therapy in Treating Patients With Kidney Cancer That is Metastatic or Cannot Be Removed by Surgery

Recurrent Renal Cell Carcinoma | Stage III Renal Cell Cancer | Stage IV Renal Cell Cancer | Clear Cell Sarcoma of the Kidney

United States, Netherlands
National Cancer Institute (NCI)

Completed

Trebananib With or Without Bevacizumab, Pazopanib Hydrochloride, Sorafenib Tosylate, or Sunitinib Malate in Treating Patients With Advanced Kidney Cancer

Advanced Renal Cell Carcinoma | Stage III Renal Cell Cancer AJCC v7 | Stage IV Renal Cell Cancer AJCC v7 | Advanced Sarcomatoid Renal Cell Carcinoma

United States
Federation Francophone de Cancerologie Digestive

Completed

Chemoembolization of the Liver With or Without Sunitinib Malate in Treating Patients With Liver Cancer (SATURNE)

Liver Cancer

France
National Cancer Institute (NCI)

Completed

Pemetrexed and/or Sunitinib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer

Recurrent Non-Small Cell Lung Carcinoma | Stage IV Non-Small Cell Lung Cancer AJCC v7 | Stage IIIB Non-Small Cell Lung Cancer AJCC v7

United States
National Cancer Institute (NCI)
NCIC Clinical Trials Group; Southwest Oncology Group; Cancer and Leukemia Group...

Completed

Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery (ASSURE)

Clear Cell Renal Cell Carcinoma | Stage III Renal Cell Cancer AJCC v7 | Stage II Renal Cell Cancer AJCC v7 | Stage I Renal Cell Cancer AJCC v6 and v7

United States, Canada, Puerto Rico
Graybug Vision

Completed

A Depot Formulation of Sunitinib Malate (GB-102) Compared to Aflibercept in Subjects With Wet AMD (ALTISSIMO)

Neovascular Age-Related Macular Degeneration

United States
Bristol-Myers Squibb
Ono Pharmaceutical Co. Ltd

Completed

Nivolumab (BMS-936558; MDX-1106) in Combination With Sunitinib, Pazopanib, or Ipilimumab in Subjects With Metastatic Renal Cell Carcinoma (RCC) (CheckMate 016)

Renal Cell Carcinoma | Clear-cell Metastatic Renal Cell Carcinoma

United States, Canada
Graybug Vision

Completed

A Depot Formulation of Sunitinib Malate (GB-102) in Subjects With Diabetic Macular Edema and Retinal Vein Occlusion

Diabetic Macular Edema | Retina Vein Occlusion

United States
OHSU Knight Cancer Institute
National Cancer Institute (NCI); Oregon Health and Science University

Terminated

Targeted Therapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia

Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Chronic Myelomonocytic Leukemia | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Recurrent Acute Lymphoblastic Leukemia | Refractory Acute Lymphoblastic Leukemia

United States
M.D. Anderson Cancer Center
Novartis

Terminated

Everolimus Versus Sunitinib in Non-Clear Cell Renal Cell Carcinoma

Kidney Cancer

United States
Rutgers, The State University of New Jersey
National Cancer Institute (NCI); Rutgers Cancer Institute of New Jersey

Terminated

Sunitinib and Irradiated Donor Lymphocytes in Treating Patients With Metastatic Kidney Cancer

Kidney Cancer

United States
UNICANCER

Completed

Sunitinib as First-Line Therapy in Treating Patients With Locally Advanced Metastatic Papillary Renal Cell Cancer

Kidney Cancer

France
National Cancer Institute (NCI)

Completed

Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or Metastatic Kidney Cancer

Clear Cell Renal Cell Carcinoma | Stage III Renal Cell Cancer AJCC v7 | Stage IV Renal Cell Cancer AJCC v7 | Metastatic Kidney Carcinoma

United States
Amsterdam UMC, location VUmc

Unknown

Pulsatile High-dose Sunitinib Versus TAS-102 in Patients With Metastatic Colorectal Carcinoma (mCRC) (SUNRISE-CRC)

Colorectal Cancer | Metastasis

Netherlands
Jonsson Comprehensive Cancer Center
Pfizer; Schering-Plough

Completed

Temozolomide and Sunitinib Malate in Treating Patients With Stage III or Stage IV Malignant Melanoma

Metastatic Melanoma

United States
M.D. Anderson Cancer Center

Completed

Bevacizumab in Multiple Phase I Combinations

Advanced Cancer

United States
OHSU Knight Cancer Institute
National Cancer Institute (NCI)

Completed

Personalized Kinase Inhibitor Therapy Combined With Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia

Acute Myeloid Leukemia | Acute Lymphoblastic Leukemia

United States
M.D. Anderson Cancer Center
Pfizer

Completed

Sunitinib Scheduling in Metastatic Renal Cell Carcinoma (mRCC)

Kidney Cancer | Genitourinary Cancer

United States
National Cancer Institute (NCI)
NRG Oncology

Completed

Sunitinib Malate in Treating Patients With Persistent or Recurrent Clear Cell Ovarian Cancer

Recurrent Ovarian Carcinoma | Ovarian Clear Cell Adenocarcinoma

United States, Korea, Republic of
National Cancer Institute (NCI)

Completed

Sunitinib Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer

Uterine Carcinosarcoma | Recurrent Uterine Corpus Carcinoma | Endometrial Endometrioid Adenocarcinoma | Endometrial Serous Adenocarcinoma | Endometrial Adenocarcinoma | Stage IVA Uterine Corpus Cancer AJCC v7 | Stage IVB Uterine Corpus Cancer AJCC v7 | Uterine Corpus Carcinosarcoma

United States, Canada

Search clinical trials for: Sunitinib Malate

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Estonia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations